Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting...
This marks the first and only time that an individualized T cell therapy has been approved by the FDA for a solid tumor cancer.
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...
The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions.
PRINCETON, N.J.--(BUSINESS WIRE)--Feb 14, 2024--